Atigliflozin is an orally active, selective SGLT-2 inhibitor with IC50 values of 10 nM and 8.2 μM for hSGLT-2 and hSGLT-1, respectively; it lowers blood glucose levels and improves impaired oral glucose tolerance; it can be used in the research of type II diabetes.